Abstract

BackgroundOsteoporosis is a common metabolic bone disease, which always leads to osteoporotic fractures. Biomarkers of bone mineral density (BMD) are helpful for prevention and early diagnosis of osteoporosis. This study aims to identify metabolomic biomarkers of low BMD.MethodsWe included 701 participants who had BMD measures by dual-energy X-ray absorptiometry scans and donated fasting plasma samples from three clinical centres as a discovery set and another 278 participants from the fourth centre as an independent replication set. We used a liquid chromatography-mass spectrometry-based metabolomics approach to profile the global metabolites of fasting plasma.FindingsAmong the 265 named metabolites identified in our study, six were associated with low BMD (FDR-adjusted P<0.05) in the discovery set and were successfully validated in the independent replication set. The circulating levels of five metabolites, i.e., inosine, hypoxanthine, PC (O-18:0/22:6), SM (d18:1/21:0) and isoleucyl-proline were associated with decreased odds of low BMD, and PC (16:0/18:3) level was associated with increased odds of low BMD. Per 1-SD increase in a composite metabolite score of these six metabolites was associated with about half decreased odds of low BMD (odds ratio 0.59, 95% confidence interval: 0.52-0.68). Furthermore, introduction of a panel of metabolites selected by elastic net regression to a prediction model of classical risk factors and plasma biomarker of bone resorption substantially improved the prediction performance for low BMD (AUCs: 0.782 vs. 0.698, P=0.002).InterpretationMetabolomics profiling may help identify novel biomarkers of low BMD and be helpful for early diagnosis of osteoporosis beyond the current clinical index.FundingThis study was supported by the National Key R&D Program of China [2018YFC2001500 to J.S.], Shanghai Municipal Science and Technology Major Project [2017SHZDZX01], the National Natural Science Foundation of China [Key Program, 91749204 to J.S.], the National Natural Science Foundation of China [General Program, 81771491 to J.S.], the Project of Shanghai Subject Chief Scientist [2017BR011 to J.S.], Grants from the TCM Supported Project [18431902300 to J.S.] from the Science and Technology Commission of Shanghai Municipality, and the National Natural Science Foundation of China [General Program, 81972089 to Z.X.]. Y.Z. was supported by the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, and the National Natural Science Foundation of China [81973032].

Highlights

  • Osteoporosis, a chronic condition characterized by a decrease in bone mineral density (BMD), structural deterioration of microarchitecture, and skeletal fragility,[1] is emerging as a global epidemic as people have a longer lifespan

  • We found several plasma metabolites were associated with low BMD, and a panel of selected metabolites significantly improved the performance of the model of classical risk factors and a bone resorption marker at distinguishing low BMD group from normal BMD group

  • The levels of 5 metabolites were associated with a higher prevalence of low BMD status (OR per 1-standard deviation (SD) ranged from 1.26 to 1.34), while most metabolites were associated with a decreased prevalence of low BMD status (ORs per 1-SD ranged from 0.61 to 0.80)

Read more

Summary

Introduction

Osteoporosis, a chronic condition characterized by a decrease in bone mineral density (BMD), structural deterioration of microarchitecture, and skeletal fragility,[1] is emerging as a global epidemic as people have a longer lifespan. Biomarkers of bone mineral density (BMD) are helpful for prevention and early diagnosis of osteoporosis. This study aims to identify metabolomic biomarkers of low BMD. Findings: Among the 265 named metabolites identified in our study, six were associated with low BMD (FDRadjusted P

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call